Erasca, Inc.
Erasca, Inc. is listed today as Erasca, Inc.: market value, financials and filings are on its company page.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Apr 2020 | $125 M | No. 2 | $50 to $250 million | equity | SEC | |
| Oct 2018 | $58 M | No. 1 | $50 to $250 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Erasca, Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2020).
SEC Form D · Apr 2020
The industry group it chose in its notices: Biotechnology.
SEC Form D · Apr 2020
That is all the official record says: Erasca, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Erasca, Inc. are on record.
Investors#
10 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Alexander W. Casdin | Person | not stated | not stated | Held Series A preferred stock, director (Form 3, 2021) | SEC Form 3 |
| ARCH Venture Fund X, L.P. | Venture capital | not stated | not stated | Held Series A, B-1 and B-2 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| ARCH Venture Fund X Overage, L.P. | Venture capital | not stated | not stated | Held Series A, B-1 and B-2 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| ARCH Venture Partners X, LLC | Venture capital | not stated | not stated | Held Series A, B-1 and B-2 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| ARCH Venture Partners X, L.P. | Venture capital | not stated | not stated | Held Series A, B-1 and B-2 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| ARCH Venture Partners X Overage, L.P. | Venture capital | not stated | not stated | Held Series A, B-1 and B-2 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| City Hill, LLC | Other | not stated | not stated | Held Series A, B-1 and B-2 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Cormorant Asset Management, LP | Fund or asset manager | not stated | not stated | Held Series A, B-1 and B-2 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Cormorant Global Healthcare Master Fund, LP | Fund or asset manager | not stated | not stated | Held Series A, B-1 and B-2 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Cormorant Private Healthcare Fund II, LP | Fund or asset manager | not stated | not stated | Held Series A, B-1 and B-2 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 46 investors.
Largest shareholders today
Institutions holding Erasca, Inc. shares, as of Sep 30, 2026.
- Frazier Life Sciences Management, L.P.$432 M8.40%
- BlackRock, Inc.$348 M6.76%
- RTW Investments, LP$329 M6.40%
- Venrock Adviser, LLC$295 M5.72%
- T. Rowe Price Investment Management, Inc.$252 M4.90%
- Vanguard Capital Management LLC$204 M3.96%
- State Street Corp$203 M3.94%
- Siren, L.L.C.$193 M3.76%
- Capital World Investors$137 M2.67%
- Price T Rowe Associates Inc /MD/$127 M2.47%
- Vanguard Portfolio Management LLC$124 M2.41%
- Paradigm Biocapital Advisors LP$117 M2.28%
- ARCH Venture Management, LLC$104 M2.02%
- Geode Capital Management, LLC$99 M1.92%
- Logos Global Management LP$86 M1.68%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Jonathan E. Lim, M.D. | Executive Chairman, CEO, President, Treasurer, Secretary | Apr 2020 |
| Gary E. Yeung, CFA | Chief Business Officer | Mar 2019 |
| Gary Yeung, CFA | Chief Business Officer | Jan 2019 |
| Jonathan Lim, M.D. | President and Executive Chairman | Jan 2019 |
| Alexander W. Casdin | Director | Apr 2020 |
| James A. Bristol, Ph.D. | Director | Apr 2020 |
| Jonathan E. Lim, M.D. | Director | Apr 2020 |
| Pratik S. Multani, M.D. | Director | Apr 2020 |
| Valerie S. Harding-Start | Director | Apr 2020 |
| Jonathan Lim, M.D. | President and Executive Chairman | Jan 2019 |
Went public since 2021. Its SEC number is that of a company listed on a stock exchange.